- Thinly traded nano cap Neurotrope (NASDAQ:NTRP) is up 4% premarket on light volume in reaction to its Cooperative Research and Development Agreement with the National Cancer Institute aimed at launching a Phase 1 clinical trial evaluating Bryostatin-1 in children and young adults with CD22-positive leukemia and B-cell lymphoma.
- NCI's Nirali Shah, M.D. will be lead investigator.